AC Immune to Decide This Year on IPO or Sale as Roche Tests Drug

AC Immune, the Swiss developer of an Alzheimer’s treatment licensed to Roche Holding AG, will decide this year whether to pursue an initial public offering or a sale after Roche said it would start late-stage trials of the experimental drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.